We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.34B
1-Year Est. Return
204.53%
This Fund
S&P 500
This Quarter
Est. Return
+50.74%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.05B
AUM Growth
+$305M
(+41%)
Cap. Flow
+$94.6M
Cap. Flow
% of AUM
8.98%
Top 10 Holdings %
Top 10 Hldgs %
64.97%
Holding
54
New
17
Increased
9
Reduced
10
Closed
10
Top Buys
| 1 |
AnaptysBio
ANAB
|
+$46.5M |
| 2 |
Arvinas
ARVN
|
+$39.2M |
| 3 |
Assembly Biosciences
ASMB
|
+$35.2M |
| 4 |
IPHA
Innate Pharma
IPHA
|
+$27.9M |
| 5 |
MRUS
Merus
MRUS
|
+$25M |
Top Sells
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$69.3M |
| 2 |
argenx
ARGX
|
+$44.5M |
| 3 |
Solid Biosciences
SLDB
|
+$34.6M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$14.3M |
| 5 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
+$8.42M |
Sector Composition
| 1 | Healthcare | 92.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$441M
| $149M | 14.16% |
9,426,640
| – | – |
|
2
Xencor
XNCR
$1.11B
| $86M | 8.16% |
2,501,557
| – | – |
|
|
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $79.9M | 7.58% |
3,627,597
-335,381
| -8% | -$6.75M |
|
|
KYNB
4
Kyntra Bio
KYNB
$29.2M
| $64M | 6.07% |
59,689
+7,937
| +15% | +$8.1M |
|
5
Kura Oncology
KURA
$1.01B
| $58.3M | 5.53% |
4,241,953
+200,000
| +5% | +$2.96M |
|
6
Ironwood Pharmaceuticals
IRWD
$658M
| $58.2M | 5.52% |
4,371,408
-300,000
| -6% | -$3.31M |
|
|
7
Arvinas
ARVN
$534M
| $55M | 5.22% |
+1,339,069
| New | +$39.2M |
|
|
8
Assembly Biosciences
ASMB
$530M
| $48.9M | 4.64% |
199,022
+190,972
| +2,372% | +$35.2M |
|
9
Neurogene
NGNE
$787M
| $48.2M | 4.58% |
195,794
+82,500
| +73% | +$8.22M |
|
|
MORF
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $37M | 3.51% |
2,154,845
-6,675
| -0.3% | -$104K |
|
|
PRVL
11
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $35.6M | 3.38% |
2,248,306
-144,250
| -6% | -$1.84M |
|
|
12
argenx
ARGX
$54B
| $32.4M | 3.08% |
202,117
-329,048
| -62% | -$44.5M |
|
|
13
AnaptysBio
ANAB
$1.65B
| $31.9M | 3.03% |
+1,966,100
| New | +$46.5M |
|
|
IPHA
14
Innate Pharma
IPHA
$169M
| $29.3M | 2.78% |
+4,545,454
| New | +$27.9M |
|
|
MRUS
15
DELISTED
Merus
MRUS
| $24.2M | 2.3% |
1,718,200
+1,552,600
| +938% | +$25M |
|
|
BCEL
16
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $22.9M | 2.17% |
1,481,411
| – | – |
|
17
Acadia Pharmaceuticals
ACAD
$4.44B
| $21.4M | 2.03% |
+500,000
| New | +$21.8M |
|
|
CHMA
18
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $15.1M | 1.43% |
3,043,827
| – | – |
|
|
HARP
19
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $13.4M | 1.27% |
90,855
-55,487
| -38% | -$8.42M |
|
|
SAGE
20
DELISTED
Sage Therapeutics
SAGE
| $12.5M | 1.19% |
+173,364
| New | +$21.3M |
|
21
Ultragenyx Pharmaceutical
RARE
$3.12B
| $11.2M | 1.06% |
261,554
+200,000
| +325% | +$8.25M |
|
22
Cartesian Therapeutics
RNAC
$255M
| $10.9M | 1.04% |
+153,257
| New | +$7.39M |
|
23
Exicure
XCUR
$10.3M
| $10.1M | 0.96% |
23,628
-13,140
| -36% | -$5.38M |
|
|
PVLA
24
Palvella Therapeutics
PVLA
$2.18B
| $9.18M | 0.87% |
+31,690
| New | +$8.79M |
|
25
Fate Therapeutics
FATE
$349M
| $8.83M | 0.84% |
+451,354
| New | +$7.17M |
|
Similar funds
G
MC
BAM
CC
HFM
NO
ST
MFAM